Indications for: ADUHELM
Alzheimer's disease in mild cognitive impairment or mild dementia.
See full labeling. Initiate titration based on dosing schedule. Give by IV infusion over 1hr every 4 weeks. Infusions 1 and 2: 1mg/kg. Infusions 3 and 4: 3mg/kg. Infusions 5 and 6: 6mg/kg. Infusion 7 and beyond: 10mg/kg.
Risk for amyloid related imaging abnormalities (ARIA), either with edema (ARIA-E), or with hemosiderin deposition (ARIA-H). Consider testing for ApoE ε4 carrier status to determine the risk for ARIA prior to treatment initiation. Risk for intracerebral hemorrhage: prior intracerebral hemorrhage >1cm in diameter, >4 microhemorrhages, superficial siderosis, history of diffuse white matter disease. Perform clinical evaluation if ARIA symptoms occur (esp during titration), including MRI testing if indicated. Obtain recent MRI (within 1yr) prior to initiation, and prior to 5th, 7th, 9th, and 12th infusions. Discontinue if hypersensitivity reactions occur. Pregnancy. Nursing mothers.
Amyloid beta-directed antibody.
Caution when considering concomitant antithrombotics or a thrombolytic agent (eg, tissue plasminogen activator).
ARIA-Edema, headache, ARIA-H microhemorrhage, ARIA-H superficial siderosis, fall; hypersensitivity reactions.
Half-life: 24.8 days.
Generic Drug Availability:
Single-dose vial (1.7mL, 3mL)—1